Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Eylea

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.

Early knockback for AbbVie as FDA rejects Allergan eye drug

Early knockback for AbbVie as FDA rejects Allergan eye drug

Abcipar pegol was given every two or three months in phase 3 testing, which compares to monthly dosing with Lucentis and Bayer’s rival anti-VEGF drug Eylea (aflibercept), which is ... Meanwhile, Novartis recently claimed approval for Beovu (brolucizumab

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD year. Bayer hasn’t reported its fourth-quarter results yet, but made $1.8bn from Eylea in other markets in the first nine months of the year. ... The company is also trumpeting Beovu’s less frequent dosing schedule compared to Eylea.

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture s Eylea (aflibercept), which together account for the lion’s share of the wet AMD market by value. ... Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma are among companies which are working on Lucentis

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD Head-to-head trial with rival Eylea could boost sales. The FDA has approved Novartis’ new VEGF inhibitor Beovu as a new treatment option for patients with the wet form of ... That compares to four to eight week dosing with Eylea, and every month with

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner Regeneron will however take the lead on eye disease candidates, a category in which it is already strong with blockbuster age-related macular degeneration (AMD) therapy Eylea (aflibercept), with Alnylam in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics